Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLK3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PLK3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLK3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLK3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLK3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00000774 | Oral cavity | OSCC | DNA damage checkpoint | 67/7305 | 115/18723 | 2.20e-05 | 2.08e-04 | 67 |
GO:00714569 | Oral cavity | OSCC | cellular response to hypoxia | 84/7305 | 151/18723 | 2.46e-05 | 2.30e-04 | 84 |
GO:00447744 | Oral cavity | OSCC | mitotic DNA integrity checkpoint | 52/7305 | 85/18723 | 2.86e-05 | 2.64e-04 | 52 |
GO:00447734 | Oral cavity | OSCC | mitotic DNA damage checkpoint | 50/7305 | 81/18723 | 2.87e-05 | 2.64e-04 | 50 |
GO:003629417 | Oral cavity | OSCC | cellular response to decreased oxygen levels | 88/7305 | 161/18723 | 3.91e-05 | 3.43e-04 | 88 |
GO:00069706 | Oral cavity | OSCC | response to osmotic stress | 50/7305 | 84/18723 | 1.11e-04 | 8.15e-04 | 50 |
GO:00315717 | Oral cavity | OSCC | mitotic G1 DNA damage checkpoint | 22/7305 | 30/18723 | 1.43e-04 | 1.01e-03 | 22 |
GO:00483082 | Oral cavity | OSCC | organelle inheritance | 13/7305 | 15/18723 | 2.07e-04 | 1.36e-03 | 13 |
GO:00483132 | Oral cavity | OSCC | Golgi inheritance | 13/7305 | 15/18723 | 2.07e-04 | 1.36e-03 | 13 |
GO:00448197 | Oral cavity | OSCC | mitotic G1/S transition checkpoint | 22/7305 | 31/18723 | 3.11e-04 | 1.94e-03 | 22 |
GO:006168410 | Oral cavity | OSCC | chaperone-mediated autophagy | 13/7305 | 16/18723 | 7.05e-04 | 3.89e-03 | 13 |
GO:20000455 | Oral cavity | OSCC | regulation of G1/S transition of mitotic cell cycle | 74/7305 | 142/18723 | 1.01e-03 | 5.24e-03 | 74 |
GO:00434916 | Oral cavity | OSCC | protein kinase B signaling | 103/7305 | 211/18723 | 2.29e-03 | 1.02e-02 | 103 |
GO:19028064 | Oral cavity | OSCC | regulation of cell cycle G1/S phase transition | 84/7305 | 168/18723 | 2.38e-03 | 1.05e-02 | 84 |
GO:00513024 | Oral cavity | OSCC | regulation of cell division | 87/7305 | 177/18723 | 3.75e-03 | 1.55e-02 | 87 |
GO:00324652 | Oral cavity | OSCC | regulation of cytokinesis | 49/7305 | 92/18723 | 3.81e-03 | 1.57e-02 | 49 |
GO:00069773 | Oral cavity | OSCC | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
GO:0010498110 | Oral cavity | LP | proteasomal protein catabolic process | 224/4623 | 490/18723 | 9.57e-25 | 4.00e-22 | 224 |
GO:0043161110 | Oral cavity | LP | proteasome-mediated ubiquitin-dependent protein catabolic process | 190/4623 | 412/18723 | 1.08e-21 | 2.93e-19 | 190 |
GO:0042176110 | Oral cavity | LP | regulation of protein catabolic process | 177/4623 | 391/18723 | 3.00e-19 | 5.87e-17 | 177 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLK3 | SNV | Missense_Mutation | | c.1585N>A | p.Leu529Met | p.L529M | Q9H4B4 | protein_coding | tolerated(0.51) | possibly_damaging(0.516) | TCGA-AR-A24M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
PLK3 | SNV | Missense_Mutation | | c.1166C>T | p.Ala389Val | p.A389V | Q9H4B4 | protein_coding | tolerated(0.35) | benign(0.001) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
PLK3 | insertion | In_Frame_Ins | novel | c.432_433insCGCCGAGCAGGGCGTGGGCACTTGACCCCC | p.Arg144_Lys145insArgArgAlaGlyArgGlyHisLeuThrPro | p.R144_K145insRRAGRGHLTP | Q9H4B4 | protein_coding | | | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PLK3 | insertion | Frame_Shift_Ins | novel | c.530_531insAATCCAGGCAGCG | p.His177GlnfsTer23 | p.H177Qfs*23 | Q9H4B4 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLK3 | SNV | Missense_Mutation | novel | c.1543T>C | p.Ser515Pro | p.S515P | Q9H4B4 | protein_coding | tolerated(0.1) | possibly_damaging(0.53) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PLK3 | SNV | Missense_Mutation | | c.512N>T | p.Ser171Phe | p.S171F | Q9H4B4 | protein_coding | deleterious(0) | possibly_damaging(0.506) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PLK3 | SNV | Missense_Mutation | rs755159184 | c.929N>A | p.Arg310His | p.R310H | Q9H4B4 | protein_coding | tolerated(0.09) | benign(0.227) | TCGA-ZJ-AAXD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PLK3 | insertion | In_Frame_Ins | novel | c.1910_1911insTACCTG | p.Leu637_Arg638insThrTrp | p.L637_R638insTW | Q9H4B4 | protein_coding | | | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
PLK3 | SNV | Missense_Mutation | novel | c.952N>C | p.Tyr318His | p.Y318H | Q9H4B4 | protein_coding | tolerated(0.05) | possibly_damaging(0.811) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLK3 | deletion | Frame_Shift_Del | | c.1006delN | p.Asn338ThrfsTer35 | p.N338Tfs*35 | Q9H4B4 | protein_coding | | | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | TAE-684 | TAE-684 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 178102294 | BI-2536 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | RG-1530 | RG-1530 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GW843682X | GW843682X | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | WORTMANNIN | WORTMANNIN | 17135248 |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | LINIFANIB | LINIFANIB | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GS 6201 | GS 6201 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | PHA-767491 | CHEMBL225519 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565601 | ONVANSERTIB | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GNF-PF-2301 | CHEMBL578061 | |